These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31447679)

  • 1. Considerations for an
    Guth BD; Engwall M; Eldridge S; Foley CM; Guo L; Gintant G; Koerner J; Parish ST; Pierson JB; Ribeiro AJS; Zabka T; Chaudhary KW; Kanda Y; Berridge B
    Front Pharmacol; 2019; 10():884. PubMed ID: 31447679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for an
    Ribeiro AJS; Guth BD; Engwall M; Eldridge S; Foley CM; Guo L; Gintant G; Koerner J; Parish ST; Pierson JB; Brock M; Chaudhary KW; Kanda Y; Berridge B
    Front Pharmacol; 2019; 10():934. PubMed ID: 31555128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the utility of LVdP/dt
    Pugsley MK; Guth B; Chiang AY; Doyle JM; Engwall M; Guillon JM; Hoffmann PK; Koerner JE; Mittelstadt SW; Pierson JB; Rossman EI; Sarazan DR; Parish ST
    J Pharmacol Toxicol Methods; 2017; 85():1-21. PubMed ID: 28065821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates.
    Markert M; Klumpp A; Trautmann T; Mayer K; Stubhan M; Guth B
    J Pharmacol Toxicol Methods; 2007; 56(2):203-11. PubMed ID: 17583538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes.
    Pointon A; Harmer AR; Dale IL; Abi-Gerges N; Bowes J; Pollard C; Garside H
    Toxicol Sci; 2015 Apr; 144(2):227-37. PubMed ID: 25538221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.
    Guth BD; Chiang AY; Doyle J; Engwall MJ; Guillon JM; Hoffmann P; Koerner J; Mittelstadt S; Ottinger S; Pierson JB; Pugsley MK; Rossman EI; Walisser J; Sarazan RD
    J Pharmacol Toxicol Methods; 2015; 75():70-90. PubMed ID: 25843226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microengineered platforms for characterizing the contractile function of in vitro cardiac models.
    Dou W; Malhi M; Zhao Q; Wang L; Huang Z; Law J; Liu N; Simmons CA; Maynes JT; Sun Y
    Microsyst Nanoeng; 2022; 8():26. PubMed ID: 35299653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward improved myocardial maturity in an organ-on-chip platform with immature cardiac myocytes.
    Sheehy SP; Grosberg A; Qin P; Behm DJ; Ferrier JP; Eagleson MA; Nesmith AP; Krull D; Falls JG; Campbell PH; McCain ML; Willette RN; Hu E; Parker KK
    Exp Biol Med (Maywood); 2017 Nov; 242(17):1643-1656. PubMed ID: 28343439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of endpoint variability and implications for study statistical power and sample size in conscious instrumented dogs.
    Chiang AY; Guth BD; Pugsley MK; Foley CM; Doyle JM; Engwall MJ; Koerner JE; Parish ST; Dustan Sarazan R
    J Pharmacol Toxicol Methods; 2018; 92():43-51. PubMed ID: 29505899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: model optimisation and evaluation.
    Adeyemi O; Roberts S; Harris J; West H; Shome S; Dewhurst M
    J Pharmacol Toxicol Methods; 2009; 60(2):159-66. PubMed ID: 19616109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
    Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
    Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
    Takasuna K; Kazusa K; Hayakawa T
    Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult Human Primary Cardiomyocyte-Based Model for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-arrhythmia Risk.
    Nguyen N; Nguyen W; Nguyenton B; Ratchada P; Page G; Miller PE; Ghetti A; Abi-Gerges N
    Front Physiol; 2017; 8():1073. PubMed ID: 29311989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of AL 107, a novel semisynthetic cardiac glycoside, on the cardiovascular system in anaesthetized beagle dogs with pentobarbital-induced cardiac insufficiency.
    Kögel B; Schneider J; Gleitz J; Wilffert B; Peters T
    Arzneimittelforschung; 1999 Aug; 49(8):679-84. PubMed ID: 10483514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac contractility and structure are not significantly compromised even during the late, hypodynamic stage of sepsis.
    Zhou M; Wang P; Chaudry IH
    Shock; 1998 May; 9(5):352-8. PubMed ID: 9617885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
    Clements M; Millar V; Williams AS; Kalinka S
    Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.